Evidence map›Paper›PMID 39654978›Full record

ArticleFrontiers in cellular and infection microbiology2024

The antipsychotic drug lurasidone inhibits coronaviruses by affecting multiple targets.

Sara Baroni, Tea Carletti, Manuela Donalisio, Irene Arduino, Irene Cazzaniga, Toni Giorgino, Francesca Esposito, Alessia Porta, Luisa Diomede, Ada De Luigi and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sara BaroniDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milano, Italy.
Tea CarlettiLaboratory of Molecular Virology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
Manuela DonalisioDipartimento di Scienze Cliniche e Biologiche, Università di Torino, Regione Gonzole, Turin, Italy.
Irene ArduinoDipartimento di Scienze Cliniche e Biologiche, Università di Torino, Regione Gonzole, Turin, Italy.
Irene CazzanigaDipartimento di Bioscienze, Università degli Studi di Milano, Milano, Italy.
Toni GiorginoConsiglio Nazionale delle Ricerche, Istituto di Biofisica, Milano, Italy.
Francesca EspositoDepartment of Life and Environmental Sciences, University of Cagliari, Monserrato, Italy.
Alessia PortaDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milano, Italy.
Luisa DiomedeDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milano, Italy.
Ada De LuigiDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milano, Italy.
Marco GobbiDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milano, Italy.
David LemboDipartimento di Scienze Cliniche e Biologiche, Università di Torino, Regione Gonzole, Turin, Italy.
Alessandro MarcelloLaboratory of Molecular Virology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
Enzo TramontanoDepartment of Life and Environmental Sciences, University of Cagliari, Monserrato, Italy.
Mario MilaniConsiglio Nazionale delle Ricerche, Istituto di Biofisica, Milano, Italy.
Eloise MastrangeloDipartimento di Bioscienze, Università degli Studi di Milano, Milano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronaviruses (CoVs) share key genomic elements critical for viral replication, suggesting the feasibility of developing therapeutics with efficacy across different viruses. In a previous work, we demonstrated the antiviral activity of the antipsychotic drug lurasidone against both SARS-CoV-2 and HCoV-OC43. In this study, our investigations on the mechanism of action of lurasidone suggested that the drug exhibits antiviral activity by targeting the papain-like protease (PL-Pro) of both viruses, and the Spike protein of SARS-CoV-2, thereby hampering both the entry and the viral replication.

Indexed as

Antipsychotic AgentsAntiviral AgentsLurasidone HydrochlorideSARS-CoV-2Virus ReplicationAnimalsChlorocebus aethiopsCoronavirus OC43, HumanCoronavirus Papain-Like ProteasesCOVID-19 Drug TreatmentHumansSpike Glycoprotein, CoronavirusVero CellsViral LoadVirus InternalizationAntipsychotic AgentsAntiviral AgentsCoronavirus Papain-Like ProteasesLurasidone Hydrochloridepapain-like protease, SARS-CoV-2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ACE2 interactioncoronavirusesdual-target compoundpapain-like proteaseSpike protein

Identifiers

PMID39654978
PMCPMC11625747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.